VERIGRAFT reports continued clinical progress during the fourth quarter of 2025.
During the quarter, VERIGRAFT submitted an application to initiate a multicenter pivotal Phase II/III clinical trial (TECVI-2), evaluating the company’s patient-specific tissue therapy, the Personalized Tissue Engineered Vein (P-TEV), for patients with severe chronic venous insufficiency. The application is currently under regulatory review within the EU clinical trial framework, with involvement of relevant regulatory authorities.
The planned clinical trial aims to confirm clinical efficacy while continuing to collect safety data in line with regulatory requirements. It builds on experience from the previously completed first-in-human clinical trial, TECVI-1.
Operational activities progressed according to plan throughout the quarter, including preparatory work related to the upcoming clinical trial program. VERIGRAFT will provide further updates as appropriate and in accordance with regulatory processes.